Last reviewed · How we verify
ALT-100
ALT-100 is an investigational immunotherapy designed to modulate immune responses, likely through targeting specific immune checkpoints or enhancing T-cell activation.
At a glance
| Generic name | ALT-100 |
|---|---|
| Sponsor | Aqualung Therapeutics Corp. |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
While specific mechanistic details for ALT-100 are limited in public literature, the drug is being developed by Aqualung Therapeutics as an immunotherapeutic agent. Given its phase 2 status and the company's focus, it likely works through immune checkpoint modulation or T-cell engineering approaches to enhance anti-tumor or anti-disease immune responses.
Approved indications
Common side effects
Key clinical trials
- Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS (PHASE2)
- First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100 (PHASE1)
- The Norwegian Nucleoside Analogue Stop Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALT-100 CI brief — competitive landscape report
- ALT-100 updates RSS · CI watch RSS
- Aqualung Therapeutics Corp. portfolio CI